Aurinia Pharmaceuticals Inc. — Director's Dealing 2021

Jan 5, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aurinia Pharmaceuticals Inc. (AUPH)
CIK: 0001600620
Period of Report: 2021-01-01

Reporting Person: Martin Michael Robert (Chief Business Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	201861	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option Grant (right to buy)	$3.02	2021-03-30	Common Stock (20000)		Direct
Option Grant (right to buy)	$3.20	2027-02-09	Common Stock (90000)		Direct
Option Grant (right to buy)	$5.30	2028-02-01	Common Stock (150000)		Direct
Option Grant (right to buy)	$6.06	2029-01-29	Common Stock (70000)		Direct
Option Grant (right to buy)	$18.38	2030-01-28	Common Stock (66900)		Direct
Option Grant (right to buy)	$13.03	2030-12-21	Common Stock (82625)		Direct

Footnotes

F1: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.

F2: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.

F3: The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date.

F4: The shares subject to the option vest in thirty-six equal monthly installments from the grant date.

F5: The shares subject to the option vest in twenty-four equal monthly installments from the grant date.

F6: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.